|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
$660,235
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
$218,588
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
$135,085
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-04
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
$392,355
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
MiRNAs in hepatocellular carcinoma development and treatment
|
5R01CA139158-07
|
$410,875
|
$205,438
|
HUANG, WENDONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-04
|
$546,873
|
$273,437
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-14
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Image-guided EMT inhibition for treating metastatic breast cancer
|
5R01CA194518-04
|
$473,853
|
$156,371
|
LU, ZHENG-RONG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-03
|
$418,127
|
$418,127
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
DICER1 and the Pleuropulmonary Blastoma Family Cancer Syndrome
|
5R01CA143167-08
|
$407,577
|
$407,577
|
HILL, DANA
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
|
1R44CA224472-01A1
|
$298,791
|
$98,601
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
2P01CA013106-46A1
|
$4,537,433
|
$635,241
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
$105,930
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
5R01CA151898-08
|
$392,969
|
$196,485
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
|
Exploring the therapeutic potential and pathogenic contribution of MTAP deletion in Glioblastoma
|
5F30CA206336-02
|
$49,524
|
$49,524
|
HANSEN, LANDON
|
DUKE UNIVERSITY
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-05
|
$2,300,000
|
$92,000
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-18
|
$672,442
|
$221,906
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-10
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
|
5R01CA207407-02
|
$371,925
|
$371,925
|
STEPHAN, MATTHIAS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Hematopoietic Chimerism after Stem Cell Allografts
|
5P01CA078902-20
|
$892,086
|
$419,280
|
STORB, RAINER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
|
5R35CA197452-04
|
$904,242
|
$904,242
|
FLORES, ELSA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Tissue-specific tumor suppressor effects of p53
|
3R01CA200256-04S1
|
$78,178
|
$39,089
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Tissue-specific tumor suppressor effects of p53
|
5R01CA200256-04
|
$409,185
|
$204,593
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
|
5R01CA204968-03
|
$506,098
|
$506,098
|
HANES, JUSTIN
|
JOHNS HOPKINS UNIVERSITY
|
|
Optimal DNA Brain-Penetrating Nanoparticle (DNA-BPN) Formulation for Glioblastoma (GBM) Treatment
|
5F31CA210610-03
|
$44,524
|
$44,524
|
NEGRON, KARINA
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
5P50CA098252-15
|
$2,251,770
|
$247,695
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Ovarian cancer gene therapy using HPV pseudovirion
|
5R01CA183040-05
|
$336,150
|
$336,150
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting glioblastoma stem-like cells with custom-designed viral vectors
|
1R42CA228875-01
|
$300,000
|
$150,000
|
WARRINGTON, KENNETH
|
LACERTA THERAPEUTICS, INC.
|
|
Histone Methyltransferases as a Target for Lung Cancer Prevention
|
5R01CA183296-05
|
$731,519
|
$365,760
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
5F30CA180731-04
|
$49,524
|
$49,524
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
|
5P01CA069246-21
|
$1,316,832
|
$579,406
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
|
4R00CA218870-03
|
$248,999
|
$248,999
|
KLEINSTIVER, BENJAMIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
|
5K99CA218870-02
|
|
$0
|
KLEINSTIVER, BENJAMIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Regulatory Pathways and Role of VPF/VEGF in Renal Cancer
|
5R01CA078383-20
|
$334,519
|
$334,519
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC JACKSONVILLE
|
|
Administrative Supplement: Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer
|
3R01CA195503-04S1
|
$55,777
|
$55,777
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
5R01CA183827-04
|
$322,194
|
$322,194
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)
|
5R01CA195503-04
|
$363,623
|
$363,623
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
|
1K01CA234324-01
|
$153,850
|
$76,925
|
NAGALO, BOLNI
|
MAYO CLINIC ARIZONA
|
|
Mechanisms of MEK/ERK growth arrest signaling
|
5R01CA138441-08
|
$308,000
|
$77,000
|
PARK, JONG-IN
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Mechanism of gp96/grp94 in regulating plasma cells and myeloma
|
5R01CA193939-03
|
$345,009
|
$172,505
|
LIU, BEI
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Self-assembled multifunctional aptamer-complex biomaterial for precision medicine
|
1R01CA224304-01
|
$369,431
|
$369,431
|
ZU, YOULI
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta
|
1R41CA224504-01A1
|
$299,956
|
$299,956
|
SETH, PREM
|
MULTIVIR, INC.
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$1,096,129
|
$164,419
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immune cell control of ovarian cancer
|
ZIA BC 011775
|
$288,423
|
$57,685
|
Annunziata, Christina
|
CCR (NCI)
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$584,022
|
$584,022
|
Beyer, Rachel
|
CCR (NCI)
|
|
Mechanisms of Chromosome Maintenance in Bacteria
|
ZIA BC 010277
|
$610,807
|
$61,081
|
Chattoraj, Dhruba
|
CCR (NCI)
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,187,757
|
$23,755
|
Cooper, Julia
|
CCR (NCI)
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,175,337
|
$293,834
|
Court, Donald
|
CCR (NCI)
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$546,995
|
$164,099
|
Fry, Terry
|
CCR (NCI)
|
Total relevant funding to Gene Therapy for this search: $35,380,030
|